ME01367B - Novi $g (y) kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže isto - Google Patents
Novi $g (y) kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže istoInfo
- Publication number
- ME01367B ME01367B MEP-2008-672A MEP67208A ME01367B ME 01367 B ME01367 B ME 01367B ME P67208 A MEP67208 A ME P67208A ME 01367 B ME01367 B ME 01367B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- formula
- crystalline form
- pharmaceutical composition
- perindopril
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title abstract description 6
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical class CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 238000010586 diagram Methods 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 16
- 229960002582 perindopril Drugs 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001882 diuretic effect Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 101800000734 Angiotensin-1 Proteins 0.000 claims description 2
- 102400000344 Angiotensin-1 Human genes 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 1
- 229960004569 indapamide Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000003940 butylamines Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Pronalazak se odnosi na kristalni oblik jedinjenja sa formulom (I) koji se karakteriše dijagramom praha (rendgenske difrakcije). Pronalazak je primenljiv za dobijanje lekova u medicini. Pronalazak se odnosi na kristalni oblik jedinjenja sa formulom (I) koji se karakteriše dijagramom praha (rendgenske difrakcije). Pronalazak je primenljiv za dobijanje lekova u medicini.
Description
Dati pronalazak odnosi se na novi y kristalni oblik tercijalne butilaminske soli perindoprila sa formulom (I):
na proces za njeno dobijanje i na farmaceutska jedinjenja koja je sadrže.
Perindopril i njegove farmaceutski prihvatljive soli, i još posebnije njegova butilaminska so, imaju značajna' farmakološka svojstva.
Njegovo najvažnije svojstvo je u tome da inhibira angiotenzin I koji prevodi enzim (ili kinazu II), koji sa jedne strane sprečava konverziju dekapeptida angiotenzina I u oktapeptidni angiotenzin II (vazokonstruktor) i sa druge strane degradaciju bradakina (vazodiletatora) do inaktivnog peptida.
Ova dve radnje odnose se na korisne efekte perindoprila kod kardiovaskularnih poremećaja, naročito arterijske hipertenzije i srčane slabosti.
Perindopril, njegovo dobijanje i njegova terapeutska upotreba opisani su u Evropskoj patentnoj prijavi EP 0 049 658.
U pogledu farmaceutske vrednosti ovog jedinjenja, od primarnog je značaja da se ono dobije u izvanredno čistom obliku. Takodje je značajno da je sposobno da se sintetizuje pomoću procesa koji se lako može konvertovati na skali industrijskih procesa, naročito u obliku koji dopušta ubrzano filtriranje i sušenje. Konačno, ovo jedinjenje mora bitku takvom obliku da se može ponovo lako dobiti, lako formulisati i da može da bude dovoljno stabilno za duži vremenski period bez posebnih zahteva u pogledu temperature, svetlosti, vlažnosti ili nivoa kiseonika.
Patentna prijava EP 0 308 341 opisuje proces inustrijske sinteze za perindopril. Medjutim, ovaj dokument ne navodi uslove dobijanja perindoprila u obliku koji izražava ove karakteristike na način na koji se mogu ponoviti.
Prijavilac je pronašao da se posebna so perindoprila, terc-butilaminska so, može dobiti u dobro definisanom, lako primenljivom kristalnom obliku koji ima značajne karakteristike formulacije.
Još specifičnije dati pronalazak se odnosi na γ kristalni oblik jedinjenja sa formulom (I), koji se karakteriše sledećim dijagramom praha, koji je meren korišćenjem Simensovog difraktometra D5005 (bakarna antikatoda) i koji je izražen _ u pogledu inter-planarnog rastojanja d, Bragovog ugla 2 teta, intenziteta i relativnog intenziteta (izraženog kao procenat od najintezivnijeg rendgentskog zraka).
Pronalazak se takodje odnosi na proces za dobijanje γ kristalnog oblika jedinjenja sa formulom (I), gde se proces karakteriše time da:
- se prema prvom izvodjenju, .rastvor tercijalne butilaminske soli perindoprila .u hloroformu zagreva na refluksu i rastvor se ubrzano hladi do 0°C dok se čvrsta supstanca ne sakupi filtracijom,
- ili, prema drugom izvodjenju, rastvor tercijalne butilaminske soli perindoprila u etilacetatu zagreva na refluksu i rastvor se ubrzano hladi izmedju o°C i 5°C dok se tako dobijena čvrsta supstanca ne sakupi filtracijom.
U procesu kristalizacije prema pronalasku moguće je koristiti jedinjenje sa formulom (I) koje se dobija u bilo kojem procesu. Koristi se jedinjenje sa formulom (I) dobijeno procesom opisanim u patentoj prijavi EP 0 308 341.
U prvom izvodjenju procesa prema pronalsku, koncentracija jedinjenja sa formulom (I) u hloroformu je po mogućstvu, od 150 do 300 g/litru.
U drugom izvodjenju procesa prema pronaalsku, koncentracija jedinjenja sa formulom (I) u etil acetatu je po mogućstvu, od 70 do 90 g/litru. Koncentracija čvrste supstance u hloroformu je po mogućstvu od 100 do 150 g/litru.
Pronalazak se odnosi takodje na farmaceutske kompozicije koje kao aktivni sastojak sadrže γ kristalni oblik jedinjenja sa formulom (I) zajedno sa jednim ili više odgovarajućih, inertnih, netoksičnih ekscipijenta. Medju farmaceutskim kompozicijama prema pronalasku, naročito se mogu pomenuti one koje su pogodne za oralnu, parantalnu (intravenoznu ili subkutanoznu) ili nazalnu primenu, tablete ili dražee, sublingvalne tablete, želatinske kapsule, pastile, čepići, kreme, masti, dermalni gelovi, preparati za ubizgavanje, suspenzije i.t.d.
Upotrebljiva doza mogu da varira prema prirodi i ozbiljnosti oboljenja, načinu davanja i uzrastu i težini pacijenta. Ona varira od 1 do 500 mg po danu kroz jednu ili više primena.
Farmaceutske kompozicije prema pronalasku takodje mogu da obuhvate diuretik, na primer kao što je inapamide.
Sledeći primeri ilustruju pronalazak ali ga ne ograničavaju na taj način.
Spektar rendgentske difrakcije meri se prema sledećim eksperimentalnim uslovima:
- Simensov D5005 difraktometar, detektor scincilacija -bakarna antikatoda (λ= 1.5405 ), voltaža 40 kV, intenzitet 40 mA -podešavanje 9-0,
-opseg merenja: 5° do 30°,
-inkrement (povećanje) izmedju svakog merenja: 0.02°,
-vreme merenja po fazi: 2s
- promenjivi razrezi: v6, filter Kβ (Ni)
- bez unutrašnje reference
- procedura dovodjenja na nulu korišćenjem Simensovog razreza, -eksperimentalni podaci dobijeni korišćenjem EVA softvera (verzija 5.0).
PRIMER 1: γ Kristalni oblik tercijalne butilaminske soli perindoprila
100 g tercijalne butilaminske soli perindoprila rastvoreno je u 500 ml hloroforma zagrevanjem na refluksu, prema procesu opisanom u patentoj prijavi EP 0 308
341. Rastvor se nakon toga hladi do 0°C, i meša se tokom noći na toj temperaturi. Čvrsti proizvod se dobija sakupljanjem procesom filtriranja.
Dijagram rendgentske difrakcije:
Profil rendgentske difrakcije (difrakcioni uglovi) za γ oblik tercijalne butilaminske soli perindoprila dat je pomoću značajnih vrednosti rendgentskih zraka sakupljeni su u sledećoj tabeli zajedno sa intenzitetom i relativnim intenzitetom izraženim u procentima za najintezivniji rendgentski zrak).
PRIMER 2: γ Kristalni oblik tercijalne butilaminske soli perindoprila
125 g tercijalne butilaminske soli perindoprila rastvoreno je u 1.5 litara etil acetata zagrevanjem na refluksu, prema procesu opisanom u patentoj prijavi EP 0 308 341.
Temperatura rastvora se nakon toga održava izmedju 0°C i 5°C.
Tako dobijena čvrsti proizvod se nakon toga sakuplja filtracijom i onda se suspenduje u 750 g hloroforma. Suspenzija se meša na sobnoj temepraturi u vremenu od 5 do 10 dana i čvrsta supstanca se onda sakuplja filtracijom.
PRIMER 3: Farmaceutska kompozicija
Preparativna formula za 100 tableta od kojih svaka sadrži 4 mg aktivnog sastojka:
Jedinjenje iz primera 1 4g
Hidroksipropilceluloza 2g
Pšenični škrob 10 g
Laktoza 100g
Magnezijum stearat 3g
Talk 3 g
Claims (11)
1. γ kristalni oblik jedinjenja sa formulom (I): koji se karakteriše sledećim dijagramom praha, koji je meren korišćenjem difraktometra (bakarna antikatoda) i koji je izražen u pogledu inter-planarnog rastojanja d, Bragovog ugla 2 teta, intenziteta i relativnog intenziteta (izraženog kao procenat od najintezivnijeg rendgentskog zraka). .
2. Proces za dobijanje γ kristalnog oblika jedinjenja sa formulom (I) prema patentnom zahtevu 1, naznačen time, što se u tom rastvoru tercijalna butilaminska so perindoprila u hloroformu zagreva na refluksu i nakon toga se hladi do 0°C i dobijena čvrsta supstanca se sakuplja filtracijom.
3. Proces za dobijanje γ kristalnog oblika jedinjenja sa formulom (I) prema patentnom zahtevu 1, naznačen time, što se u tom rastvoru tercijalna butilaminska so perindoprila u etil acetatu zagreva na refluksu i nakon toga se brzo hladi, tako dobijeni rastvor se onda sakuplja filtracijom, suspenduje se u hloroformu, suspenzija se meša na okolnoj temperaturi od 5 do 10 dana i čvrsta supstanca se onda sakuplja filtracijom. -
4.Proces ili prema patentom zahtevu 2 ili patentnom zahtevu 3, naznačen time, što se koristi jedinjenje sa formulom (I) dobijeno procesom opisanim u patentoj prijavi EP 0 308 341.
5.Proces ili prema patentom zahtevu 2, naznačen time, što je koncentracija jedinjenja sa formulom (I) u hloroformu od 150 do 300 g/litru.
6.Proces ili prema patentom zahtevu 3, naznačen time, što je koncentracija jedinjenja sa formulom (I) u etil acetatu od 70 do 90 g/litru.
7.Farmaceutska kompozicija koja kao aktivni sastojak obuhvata jedinjenje prema patentnom zahtevu 1, u kombinaciji sa jednim ili više faramceutski prihvatljivih, inertnih, netoksičnih nosača.
8. Farmaceutska kompozicija prema patentnom zahtevu 7 za upotrebu u proizvodnji lekova kao inhibitora konvertujućeg enzima, angiotenzina I.
9. Farmaceutska kompozicija prema patentnom zahtevu 8 za upotrebu u proizvodnji lekova u lečenju kardiovaskularnih oboljenja.
10.Farmaceutska kompozicija prema bilo kojem od patentnih zahteva 7 do 9, naznačena time, što takodje obuhvata diuretik.
11.Farmaceutska kompozicija prema patentnom zahtevu 10, naznačen time, što je diuretik indapamid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0008791A FR2811318B1 (fr) | 2000-07-06 | 2000-07-06 | Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| PCT/FR2001/002169 WO2001083439A2 (fr) | 2000-07-06 | 2001-07-06 | NOUVELLE FORME CRISTALLINE η DU SEL DE TERT-BUTYLAMINE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01367B true ME01367B (me) | 2013-12-20 |
Family
ID=8852170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-672A ME01367B (me) | 2000-07-06 | 2001-07-06 | Novi $g (y) kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže isto |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20030158121A1 (me) |
| EP (1) | EP1296948B1 (me) |
| JP (2) | JP3592296B2 (me) |
| KR (1) | KR100513572B1 (me) |
| CN (1) | CN1328258C (me) |
| AP (1) | AP1452A (me) |
| AR (1) | AR029570A1 (me) |
| AT (1) | ATE249435T1 (me) |
| AU (2) | AU7642001A (me) |
| BG (1) | BG66239B1 (me) |
| BR (1) | BR0112211A (me) |
| CA (1) | CA2415447C (me) |
| CZ (1) | CZ302022B6 (me) |
| DE (1) | DE60100761T2 (me) |
| DK (1) | DK1296948T3 (me) |
| EA (1) | EA004275B1 (me) |
| EE (1) | EE05286B1 (me) |
| ES (1) | ES2206423T3 (me) |
| FR (1) | FR2811318B1 (me) |
| GE (1) | GEP20043362B (me) |
| HR (1) | HRP20030078B1 (me) |
| HU (1) | HU228115B1 (me) |
| ME (1) | ME01367B (me) |
| MX (1) | MXPA02012904A (me) |
| NO (1) | NO323445B1 (me) |
| NZ (1) | NZ523311A (me) |
| OA (1) | OA12306A (me) |
| PL (1) | PL348491A1 (me) |
| PT (1) | PT1296948E (me) |
| RS (1) | RS51621B (me) |
| SI (1) | SI1296948T1 (me) |
| SK (1) | SK287452B6 (me) |
| UA (1) | UA57187C2 (me) |
| WO (1) | WO2001083439A2 (me) |
| ZA (1) | ZA200300025B (me) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2811320B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| FR2811319B1 (fr) | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| FR2834893B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible de perindopril |
| GB2395195A (en) * | 2002-11-18 | 2004-05-19 | Cipla Ltd | Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors |
| ATE540924T1 (de) * | 2003-06-24 | 2012-01-15 | Servier Lab | Neue kristalline formen von perindopril erbumine |
| AU2003263584A1 (en) * | 2003-08-21 | 2005-03-10 | Hetero Drugs Limited | Process for pure perindopril tert-butylamine salt |
| AU2003300689B2 (en) | 2003-10-21 | 2009-01-29 | Les Laboratoires Servier | Novel method for preparation of crystalline perindopril erbumine |
| SI21703A (en) | 2004-01-14 | 2005-08-31 | Lek Farmacevtska Druzba Dd | Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia |
| SI21704A (en) * | 2004-01-14 | 2005-08-31 | Lek Farmacevtska Druzba Dd | New crystal form of perindopril, procedure of its preparation, pharmaceutical preparations containing this form and their application in treatment of hypertensia |
| HRP20161602T1 (hr) * | 2004-03-29 | 2016-12-30 | Les Laboratoires Servier | Postupak priprave čvrstog farmaceutskog pripravka |
| SI21800A (sl) | 2004-05-14 | 2005-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nov postopek sinteze perindoprila |
| SI21881A (sl) | 2004-10-15 | 2006-04-30 | Diagen, Smartno Pri Ljubljani, D.O.O. | Nove kristalne oblike perindopril erbumin hidratov, postopek za njihovo pripravo in farmacevtske oblike, ki vsebujejo te spojine |
| SG125975A1 (en) * | 2005-03-11 | 2006-10-30 | Servier Lab | New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it |
| SG125976A1 (en) * | 2005-03-11 | 2006-10-30 | Servier Lab | New gama crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it |
| JP2006290825A (ja) * | 2005-04-13 | 2006-10-26 | Shiono Chemical Co Ltd | アルファ型ペリンドプリルエルブミンの製造法 |
| WO2007017894A2 (en) * | 2005-05-05 | 2007-02-15 | Arch Pharmalabs Limited | PREPARATION OF NOVEL CRYSTALLINE η(ETA) FORM OF PERINDOPRIL ERBUMINE |
| CA2618561C (en) * | 2005-08-12 | 2014-04-29 | Lek Pharmaceuticals D.D. | A process for the preparation of perindopril erbumine |
| US20090099370A1 (en) * | 2005-08-12 | 2009-04-16 | Sandoz Ag | Crystalline Form of Perindopril Erbumine |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| WO2007092758A2 (en) * | 2006-02-03 | 2007-08-16 | Dr. Reddy's Laboratories Ltd. | Crystalline forms of perindopril erbumine |
| FR2897866B1 (fr) * | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2897865B1 (fr) | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| WO2008114270A1 (en) * | 2007-03-22 | 2008-09-25 | Aarti Healthcare Limited | Process for the preparation of perindopril erbumine salt and novel polymorph (s) thereof |
| WO2008120241A2 (en) * | 2007-03-29 | 2008-10-09 | Ipca Laboratories Limited | Novel alcohol solvates of perindopril erbumine |
| SI22543A (sl) * | 2007-06-27 | 2008-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nove soli perindoprila |
| PL2318365T3 (pl) * | 2008-06-24 | 2016-02-29 | Mylan Laboratories Ltd | Nowe odmiany polimorficzne (L) argininianu peryndoprylu i sposoby ich wytwarzania |
| KR200453510Y1 (ko) * | 2009-02-09 | 2011-05-11 | 윤유원 | 튀김유 정제기 |
| KR101041878B1 (ko) * | 2009-03-26 | 2011-06-15 | 신준호 | 튀김장치용 찌꺼기 제거장치 |
| SI23149A (sl) | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
| PT105315B (pt) | 2010-09-29 | 2013-01-16 | Inst Superior Tecnico | Uma nova forma cristalina hidratada de erbumina de perindopril, métodos para a sua preparação e sua utilização em preparações farmacêuticas |
| EP3842035A1 (en) | 2019-12-23 | 2021-06-30 | KRKA, d.d., Novo mesto | Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| FR2620703B1 (fr) * | 1987-09-17 | 1991-10-04 | Adir | Procede de synthese industrielle de l'acide perhydroindole carboxylique - 2(2s, 3as, 7as). application a la synthese de carboxyalkyl dipeptides |
| FR2620709B1 (fr) * | 1987-09-17 | 1990-09-07 | Adir | Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese |
| FR2771010B1 (fr) * | 1997-11-19 | 2003-08-15 | Adir | Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires |
| FR2811320B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| FR2811319B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
-
2000
- 2000-07-06 FR FR0008791A patent/FR2811318B1/fr not_active Expired - Fee Related
-
2001
- 2001-06-07 UA UA2003021019A patent/UA57187C2/uk unknown
- 2001-07-05 HU HU0102814A patent/HU228115B1/hu not_active IP Right Cessation
- 2001-07-06 GE GE5074A patent/GEP20043362B/en unknown
- 2001-07-06 US US10/312,903 patent/US20030158121A1/en not_active Abandoned
- 2001-07-06 BR BR0112211-8A patent/BR0112211A/pt not_active Application Discontinuation
- 2001-07-06 JP JP2001580868A patent/JP3592296B2/ja not_active Expired - Fee Related
- 2001-07-06 PL PL01348491A patent/PL348491A1/xx not_active Application Discontinuation
- 2001-07-06 CN CNB018123538A patent/CN1328258C/zh not_active Expired - Fee Related
- 2001-07-06 EA EA200300104A patent/EA004275B1/ru not_active IP Right Cessation
- 2001-07-06 EE EEP200300003A patent/EE05286B1/xx not_active IP Right Cessation
- 2001-07-06 DE DE60100761T patent/DE60100761T2/de not_active Expired - Lifetime
- 2001-07-06 RS YU100302A patent/RS51621B/sr unknown
- 2001-07-06 ES ES01954060T patent/ES2206423T3/es not_active Expired - Lifetime
- 2001-07-06 SK SK150-2003A patent/SK287452B6/sk not_active IP Right Cessation
- 2001-07-06 PT PT01954060T patent/PT1296948E/pt unknown
- 2001-07-06 WO PCT/FR2001/002169 patent/WO2001083439A2/fr not_active Ceased
- 2001-07-06 AU AU7642001A patent/AU7642001A/xx active Pending
- 2001-07-06 AR ARP010103224A patent/AR029570A1/es not_active Application Discontinuation
- 2001-07-06 KR KR10-2003-7000117A patent/KR100513572B1/ko not_active Expired - Fee Related
- 2001-07-06 MX MXPA02012904A patent/MXPA02012904A/es active IP Right Grant
- 2001-07-06 OA OA1200200399A patent/OA12306A/en unknown
- 2001-07-06 HR HR20030078A patent/HRP20030078B1/xx not_active IP Right Cessation
- 2001-07-06 EP EP01954060A patent/EP1296948B1/fr not_active Expired - Lifetime
- 2001-07-06 NZ NZ523311A patent/NZ523311A/en not_active IP Right Cessation
- 2001-07-06 SI SI200130029T patent/SI1296948T1/xx unknown
- 2001-07-06 AU AU2001276420A patent/AU2001276420B2/en not_active Ceased
- 2001-07-06 DK DK01954060T patent/DK1296948T3/da active
- 2001-07-06 ME MEP-2008-672A patent/ME01367B/me unknown
- 2001-07-06 AP APAP/P/2002/002709A patent/AP1452A/en active
- 2001-07-06 CZ CZ20030358A patent/CZ302022B6/cs not_active IP Right Cessation
- 2001-07-06 AT AT01954060T patent/ATE249435T1/de active
- 2001-07-06 CA CA002415447A patent/CA2415447C/fr not_active Expired - Fee Related
-
2003
- 2003-01-02 ZA ZA200300025A patent/ZA200300025B/en unknown
- 2003-01-06 NO NO20030051A patent/NO323445B1/no not_active IP Right Cessation
- 2003-02-05 BG BG107534A patent/BG66239B1/bg unknown
-
2004
- 2004-03-29 US US10/811,727 patent/US20040248817A1/en not_active Abandoned
- 2004-07-13 JP JP2004206157A patent/JP5016184B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01367B (me) | Novi $g (y) kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže isto | |
| ME00440B (me) | Novi $g(b kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže isto | |
| RS50915B (sr) | α KRISTALNI OBLIK TERCIJALNE BUTILAMINSKE SOLI PERINDOPRILA | |
| NZ570366A (en) | Beta-crystalline form of perindopril arginine salt, method for making same, and pharmaceutical compositions containing same | |
| FI72967B (fi) | Foerfarande foer framtaellning av farmaceutiskt aktiva 2-amino-3-bensoylfenylacetamidderivat. | |
| HK1055425B (en) | A crystalline form of perindopril tert-butylamine salt |